GM-CSF/IL-3/IL-5 receptor common β chain (CD131) expression as a biomarker of antigen-stimulated CD8+ T cells
© Selleri et al; licensee BioMed Central Ltd. 2008
Received: 12 February 2008
Accepted: 15 April 2008
Published: 15 April 2008
Upon Ag-activation cytotoxic T cells (CTLs) produce IFN-γ GM-CSF and TNF-α, which deliver simultaneously pro-apoptotic and pro-inflammatory signals to the surrounding microenvironment. Whether this secretion affects in an autocrine loop the CTLs themselves is unknown.
Here, we compared the transcriptional profile of Ag-activated, Flu-specific CTL stimulated with the FLU M1:58-66 peptide to that of convivial CTLs expanded in vitro in the same culture. PBMCs from 6 HLA-A*0201 expressing donors were expanded for 7 days in culture following Flu M1:58-66 stimulation in the presence of 300 IU/ml of interleukin-2 and than sorted by high speed sorting to high purity CD8+ expressing T cells gated according to FluM1:58-66 tetrameric human leukocyte antigen complexes expression.
Ag-activated CTLs displayed higher levels of IFN-γ, GM-CSF (CSF2) and GM-CSF/IL-3/IL-5 receptor common β- chain (CD131) but lacked completely expression of IFN-γ receptor-II and IFN-stimulated genes (ISGs). This observation suggested that Ag-activated CTLs in preparation for the release of IFN-γ and GM-CSF shield themselves from the potentially apoptotic effects of the former entrusting their survival to GM-SCF. In vitro phenotyping confirmed the selective surface expression of CD131 by Ag-activated CTLs and their increased proliferation upon exogenous administration of GM-CSF.
The selective responsiveness of Ag-activated CTLs to GM-CSF may provide an alternative explanation to the usefulness of this chemokine as an adjuvant for T cell aimed vaccines. Moreover, the selective expression of CD131 by Ag-activated CTLs proposes CD131 as a novel biomarker of Ag-dependent CTL activation.
In vivo animal models suggest that the activation of CD8-expressing cytotoxic T cells (CTLs) follows a linear pattern in which an expansion phase occurring within the first week after Ag stimulation rapidly evolves into a contraction phase in which surviving memory CTLs resume a quiescent phenotype [1, 2]. During the expansion phase, Ag-activated CTLs boast a robust enhancement of effector functions including the activation of cytotoxic mechanisms and the production of pro-inflammatory cytokines such as interferon (IFN)-γ. It is believed that such activation occurs through signaling associated with the Ag-specific triggering of the T cell receptor (TCR) combined with other co-stimulatory signals. In summary, naïve and, to a certain degree, long-term memory CTL activation and expansion is dependent upon three types of stimulation ; the first is the direct interaction between the TCR and the major histocompatiblity (MHC)/epitope complex. This interaction determines the specificity of the activation. However, TCR triggering is not sufficient by itself to sustain a forceful activation and expansion of CTLs and it may lead to unresponsiveness if others stimulatory signals are not provided simultaneously. A second signaling requirement is absolved by cell-to-cell interactions involving co-stimulatory molecules expressed on the surface of Ag-presenting cells. This interaction may sustain a few cell divisions but is insufficient to induce clonal expansion and full activation of effector functions. Thus, a third signal is needed, which is provided by immune-modulatory cytokines released by Ag-presenting cells, helper T cells or other immune cells in response to pro-inflammatory signals provided by pathogens or other environmental conditions. This third signal can be modeled experimentally by the exogenous administration of pro-inflammatory cytokines such as interleukin (IL)-2 .
Recombinant human IL-2 has been extensively used for the selective in vitro expansion of CTLs naturally exposed in vivo to Ag such as tumor infiltrating lymphocytes  or vaccine-induced circulating lymphocytes . The in vitro expansion of CTLs exposed to Ag in vivo, strictly requires cytokine stimulation (as exemplified by IL-2); furthermore, in vitro stimulation in the presence of IL-2 leads not only to selective expansion of Ag-specific CTLs but also to the activation of their effector functions  paralleling the expansion phase described in other experimental models [1, 7].
Segregating the respective contribution of Ag-specific signaling and environmental co-stimulation within the same microenvironment may provide useful insights about the mechanisms involved in the selective activation of Ag-exposed CTLs within a T cell population and shed light on the requirements for full activation of CTL effector functions in the target organ during distinct immune reactions including tumor regression following immunotherapy [8, 9], acute allograft rejection , clearance of viral infection  and flares of autoimmunity .
In a simplified in vitro model of human CTL activation, we previously observed that neither Ag-stimulation in the presence of signal two nor the presence of signal 3 alone could induce in vitro expansion and activation of Ag-exposed CTLs and only the combination of the three could induce effective CTL responses . Analysis of the transcriptional patterns associated with the complete activation of effector CTL responses suggested that proliferation and effector function were both dependent upon the combined presence of the three signals. However, further dissection of transcriptional patterns induced by the administration of IL-2 to peripheral blood mononuclear cells (PBMC) or non Ag-activated CD4 and CD8 T cell sub-populations suggested that the effects of IL-2 on T cell signaling are powerful but non-specific in the absence of TCR triggering . Thus, to discriminate the individual contribution of direct TCR triggering on CTL activation, we compared the transcriptional profile of Ag-exposed CTLs to non-Ag-exposed, non-proliferating CTLs sharing identical environmental conditions. The model evaluated the kinetics of proliferation of HLA-A*0201-restricted, Flu Matrix protein epitope M1:58-66-specific CTLs; seven days following in vitro Ag stimulation with M1:58-66 and in vitro culture in 300 IU of human recombinant IL-2 (Novartis-Chiron CO, Emeryville CA), we separated with tetrameric flu-specific human leukocyte antigen/complexes (tHLA) proliferating CTLs from their companions CD8 expressing T cells (convivial CTLs).
Materials and methods
Transcriptional characteristics of stimulated versus resting CD8 expressing T cells
In vitro sensitization (IVS)
PBMCs were obtained by leukapheresis from HLA-A*0201-expressing normal volunteers and frozen after Ficoll separation. HLA-A*0201 expression was documented by sequence-based typing . PBMCs from 6 donors were thawed and plated in complete Iscove medium (Life Technologies, Grand Island, NY) supplemented with 10% heat inactivated human AB serum, 10 mM HEPES buffer, 100 U/ml penicillin-streptomycin, 0.5 mg/ml amphotericin B and 0.03% glutamine, at the density of 106 cells/well in 48 multiwell plate. After overnight panning, cells were pulsed at day 1 with 1 μM Flu M1:58-66 peptide (Princeton Biomolecules, Langhorne, PA) and the following day human recombinant IL-2 300 IU/ml (rHuIL-2, Chiron Co, Emeryville, CA) was added. IL-2 was added every two days. At day 1, T cells were stained with Carboxy Fluoroscein Succinimidyl Ester (CFSE) to monitor their proliferation. PBMC cultures were continued for 7 days till sorting.
RNA handling for transcriptional profiling
Total RNA was isolated with RNeasy minikits (Qiagen, Valencia, CA) and amplified into anti-sense RNA as previously described [15, 16]. First strand cDNA synthesis was accomplished in 1μl SUPERase·In (Ambion, Foster City, CA) and ThermoScript RT (Gibco-Invitrogen, Carlsbad, CA) in 2 μg bovine serum albumin. RNA quality was verified by Agilent technologies (Palo Alto). Anti-sense RNA was labeled with Cy5-dUTP (Amersham, Piscataway, NJ) and co-hybridized with reference pooled normal donor peripheral blood mononuclear cells (PBMC) labeled with Cy3-dUTP to custom made 17K-cDNA array platform (UniGene cluster) printed at the Infectious Disease and Immunogenetics Section, DTM, CC, NIH with a configuration of 32 × 24 × 23 and contained 17,500 elements. Clones used for printing included a combination of the Research Genetics RG_HsKG_031901 8 k clone set and 9,000 clones selected from the RG_Hs_seq_ver_070700 40 k clone set. The 17,500 spots included 12,072 uniquely named genes, 875 duplicated genes and about 4,000 expression sequence tags.
Arrays were scanned on a GenePix 4000 (Axon Instruments) and analyzed using BRB-ArrayTools Version: 3.3, Cluster and Tree View software.
Phenotyping and proliferation of Ag-activated CTLs
PBMCs from HLA-A*0201 healthy volunteers were obtained from leukapheresis by Ficoll separation and kept frozen in liquid nitrogen in aliquots of 108 cells/vial. At day 0, PBMCs (1 vial/donor) were thawed and plated in 24 mw plates (2 × 106 cells/well). After resting overnight, 105 cells/donor were stained in order to determine the percentage of CD8+ FLU+ T cells at day 1. All the remaining cells were stimulated with Flu peptide (Flu M1:58-66, 1 μg/ml, Princeton Biomolecules, Langhorne, PA). The day after cells in culture were harvested, counted and plated in new 24 mw plates (2 × 106 cells/well) and treated as follows: 1) untreated (Flu stimulation on day 1 only); 2) IL-2 (300 U/ml, Chiron, Emeryville CA); 3) IL-2+GM-CSF (103 U/ml, PreProtech, Rocky Hill, NJ); 4) GM-CSF; 5) IL-2+IFN-γ (500 U/ml, Actimmune, Brisbane, CA); 6) IFN-γ. Cytokines were added every 2 days, replacing each time half of the medium to avoid their accumulation in the supernatant. At day 6 and 12, cells from 1 well/treatment were harvested, counted and stained for FACS analysis.
Harvested cells were washed with buffer and stained with t-FLU-PE (FLU M1 iTAg MHC Tetramer, Beckman Coulter, Miami, FL), mouse IgG1k anti CD8 PE-Cy5 (Becton Dickinson, Franklin Lakes, NJ), mouse IgG2a anti GM-CSF-R (by Millipore, Billerica, MA, detected by using a secondary antibody against mouse IgG2a Alexa 647 conjugated, from Invitrogen, Carlsbad, CA), mouse IgG1k anti IFN-γ Receptor β chain (Abcam, detected by using a secondary antibody against mouse IgG1k Alexa 488 conjugated, from Invitrogen). In order to avoid the reaction of the secondary antibody used for IFNγ detection with the Fc of the IgG1k anti CD8, the staining for IFNγ receptor was performed separately and anti CD8 was added after washing as last step.
FACS analysis was performed using a FACScalibur by BD Pharmingen.
The raw data were filtered to exclude spots with minimum intensity by arbitrarily setting a minimum intensity requirement of 300 in both fluorescence channels. If the fluorescence intensity of one channel was over and that of the other below 300 the fluorescence of the low intensity channel was arbitrarily set to 300. Spots with diameters < 25 μm and flagged spots were excluded from the analysis. The filtered data were then normalized using the lowess smother correction method. All statistical analyses were performed using the log2-based ratios normalizing the normal value in the array equal to zero.
Validation and reproducibility were measured using an internal reference concordance system based on the expectation that results obtained through the hybridization of the same test and reference material in different experiments should perfectly collimate. The level of concordance was measured by periodically re-hybridizing the melanoma cell line A375-melanoma (American Type Culture Collection, Rockville MD) to the reference samples consisting of pooled PBMCs as previously described . This analysis demonstrated a higher than 95% concordance level. Non-concordant genes were excluded from subsequent analysis.
Supervised class comparison utilized the BRB ArrayTool  developed at NCI, Biometric Research Branch, Division of Cancer Treatment and Diagnosis. Paired samples were compared with a two-tailed paired Student t test. Unpaired samples were tested with a two-tailed un-paired Student t test assuming unequal variance or with an F test as appropriate. All analyses were tested for a univariate significance threshold set at a p2-value < 0.005. Gene clusters identified by the univariate t test were challenged with two alternative additional tests, a univariate permutation test (PT) and a global multivariate PT. The multivariate PT was calibrated to restrict the false discovery rate to 10%. Genes identified by univariate t test as differentially expressed (p2-value < 0.005) and a PT significance < 0.05 were considered truly differentially expressed. Gene function was assigned based on Database for Annotation, Visualization and Integrated Discovery (DAVID) and Genontology. Multiple dimensional scaling was performed using the BRB Array tool.
Fold increase in CD8+ FLU+ T cells was based on the calculation of the absolute number of CD8 expressing T cells at day 1, day 6 and day 12. Their fold increase (FI) was calculated by dividing their number at day 6 and 12 over their starting number at day 1. The same assessment was done for flu-positive and flu-negative CTLs. Average and standard error from the mean (SEM) are presented as appropriate. A paired Student t test was applied to calculate level of significance.
Results and discussion
Global Differences between Ag-stimulated, IL-2-activated and quiescent CD8 expressing T cells
Difference in the transcriptional pattern of quiescent compared to stimulated CD8 T cells
# of genes differentially expressed at Student t test or F test p2-value < 0.001
Permutation Test (p-value) Multivariate
Ex vivo vs CD8 in culture vs IL-2 vs IL-2+Flu
6,692 (F test, n = 24)
Ex vivo vs combined IL-2 and IL-2+Flu
5,527 (t test, n = 18)
Ex vivo vs IL-2 vs IL-2+Flu
4, 702 (F test, n = 18)
Ex vivo vs IL-2
4,893 (t test, n = 12)
Ex vivo vs IL-2+Flu
5, 859 (t test, n = 12)
IL-2 vs IL-2+Flu
1,727 (t test), n = 12
Analysis of individual experimental conditions against each other demonstrated that the biggest differences in transcriptional patterns were present between the Flu-specific CTLs stimulated in vitro and the quiescent ex vivo CD8 T cells (three way t test) with the least differences noted between the Flu-specific CTLs and the convivial non-Flu-specific CTLs from the same culture.
Transcriptional patterns shared by Ag-specific and convivial CTLs compared to quiescent ex vivo analyzed CD8-expressing T cells
The transcriptional pattern of in vitro stimulated CTLs whether exposed to Ag (Flu-specific CD8 T cells) or only to IL-2 was similar relative to that of ex vivo isolated or in vitro maintained CD8 T cells. In particular, multiple dimensional scaling based on the complete 16,726 gene data set clearly separated the unstimulated from the stimulated populations. Of 5,859 genes differentially expressed between Flu-specific CTLs and ex vivo CD8 T cells, 3,639 were concordantly expressed by convivial CTLs (Figure 1C). Thus, CTLs maintained in the same culture demonstrate similar transcriptional patterns independent of their exposure to Ag-specific stimulation. Among the genes similarly up-regulated in both subgroups of stimulated T cells were perforin, granzyme A, TNF-α and the IL-2 receptor α chain. Overall, the transcriptional profile of the genes concordantly expressed by in vitro stimulated CTLs was similar to that of our previous reported analysis .
Transcriptional patterns specific to Ag-specific activation
The aim of this study was to identify those signatures that are determined by the long term effects of Ag stimulation independent of other co-existing factors that may influence the activation and function of CD8+ T cells. For this reason, we focused our analysis on genes that were differentially expressed between CFSEhigh, Flu/tHLA positive CD8 T cells and CSFElow, Flu/tHLA negative CD8 T cells. An unpaired t test identified 1,727 genes to be differentially expressed between the two populations at a p2-vlue < 0.001 (Table 1). It should be clarified that several of these genes were concordantly differentially expressed in both subpopulations compared with quiescent ex vivo isolated CD8-expressing T cells. However, the degree in which the expression was altered in the two subsets was sufficiently different to result in significant differences between the two populations. The differences identified were significant according to the multivariate permutation test (p-value = 0). Multiple dimensional scaling analysis based on the complete date set confirmed the separation of the two populations (Figure 1D).
Among the genes differentially expressed by the two populations 644 were up-regulated in Ag-specific CTLs compared to convivial CTLs. The rest (1,083) were down-regulated. The annotations related to biological functions derived through gene ontology suggested that the genes that were predominantly up-regulated in Ag-specific CTLs belong to several categories. Although some categories appeared particularly enriched, they contained a relatively small number of genes, while the categories with the largest absolute number of genes included: cell cycle and cell division (111 genes), response to endogenous stimulus (45 genes) and cytokine production (17 genes). Gene Ontology analysis suggested, therefore, that even seven days after the original stimulus the predominant differences between Ag-exposed Flu-specific CTLs and their culture companions were related to a broader activation of pro-proliferative stimuli, signaling and cytokine production in the former.
Gene Ontology was also applied to identify genes associated with immunological functions; this analysis identified 58 (expected number 52.8; observed over expected ratio = 1.10) up-regulated in the Flu-specific CTLs and 212 out of 988 (expected number 80.3; observed over expected ratio = 2.64) down-regulated relative to the convivial CTLs (Fisher test p2-value < 0.001).
Immune Genes Up-regulated in Flu-specific CD8 T cells
Immune GenesUp-regulated in convivial CD8 T cells
interferon-γ receptor 2
Colony stimulating factor 2
Chemokine (C-C motif) ligand 3
Chemokine (C motif) ligand 1
STAT induced STAT inhibitor-3 = CIS3
CD80 = B7-1
Chemokine (C-X3-C motif) receptor 1
Colony stimulating factor 2 receptor, beta
Chemokine (C-C motif) receptor 7
TIMP metallopeptidase inhibitor 2
GM-CSF/IL-5/IL-3 receptor common beta chain
Platelet factor 4 (chemokine) ligand 4
Lymphocyte antigen 86
CD49F = Integrin alpha 6
CD86 = B7.2
platelet/endothelial cell adhesion molecule (CD31)
adhesion molecule DNAM-1
lymphocyte antigen 9
Chemokine (C-X-C motif) receptor 6
Janus kinase 1
Integrin, alpha 2 (CD49B)
Tumor necrosis factor superfamily13
Dual specificity phosphatase 16
Interleukin 1 receptor accessory protein
tissue inhibitor of metalloproteinase 1
C-C chemokine receptor 1
Cytokine inducible SH2-containing protein
dual specificity phosphatase 5
CD103 beta = Integrin beta 7
inducible T-cell co-stimulator
GABA-BR1a (hGB1a) receptor
Dual specificity phosphatase 10
CD62L = L-selectin
GRO1 = GRO α
IL-11 receptor α chain
IL-2 receptor beta chain
chemokine (C-X-C motif), receptor 4 (fusin)
IL-7 receptor α chain
Vascular endothelial growth factor B
interleukin 2 receptor, alpha
IL-4 receptor α chain
interferon-gamma receptor α chain
Ag-activated CTLs also expressed higher levels of granzyme B and to a lesser degree granzyme A while their convivial counterparts expressed high levels of granzyme K. As previously observed, Perforin, was strongly and equally un-regulated in both populations compared to quiescent CD-expressing T cells studied ex vivo or in vitro .
Finally, Ag-activated CTLs expressed higher levels of the co-stimulatory molecules CD80 and CD86.
GMCSF effects on Ag-specific CTLs
The high levels of IFN-γ and GMSCF transcript (but not protein) expression together it the up-regulation of CMCSF receptor β chain (CD131) and the down regulation of the IFN-γ receptors I and II by Ag-activated CTLs suggested the intriguing possibility of a bipolar relationship of Ag-activated CTLs with the potential autocrine effects of the two cytokines. It appears that Ag-activated CTLs shield themselves from the potential harmful affects of IFN-γ  while accepting the potentially proliferative support of GM-CSF; a growth factor without known pro-apoptotic functions . This bipolar behavior may explain the selective survival and expansion of Ag-stimulated CTLs in vitro (an potentially in vivo).
In conclusion, this preliminary study suggests that, at least during IVS, preferential survival/expansion of Ag-activated CTL may be partially mediated through a bipolar regulation of their sensitivity to the autocrine secretion of cytokines; IFN-γ and GMCSF appear to play a dominant role at this junction as other two cytokines known to be produced by activated CTLs (TNF-α and IL-2) where similarly highly expressed at the transcriptional level by both Ag-activated and convivial CTLs. The confirmation of the selective expression of CD131 on the surface of Ag-activated CTLs and its likely functional association with the selective response of Ag-activated CTLs to exogenous GM-CSF suggests a previously unreported positive feed back autocrine loop that may stimulate CTL growth in response to further Ag stimulation . In addition, the positive role that GMCSF may play in the proliferation of CD131-expressing Ag-activated CTLs, may explain the beneficial effects of this cytokine used as vaccine adjuvant, which has been so far attributed exclusively to its role in activating and maturing antigen presenting cells . Finally, the selective expression of CD131 by Ag-activated CTLs may qualify this surface marker as a non Ag-specific biomarker of Ag-specific CTL activation. Although extensive in vivo and in vitro validation is required to support such hypotheses, we believe that the novelty and the potential biological implications of these findings warrant a preliminary disclosure.
- Kaech SM, Hemby S, Kersh E, Ahmed R: Molecular and functional profiling of memory CD8 T cell differentiation. Cell. 2002, 111: 837-851. 10.1016/S0092-8674(02)01139-X.View ArticlePubMedGoogle Scholar
- Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, Antia R, von Andrian UH, Ahmed R: Lineage relationship and protective immunity of memory CD8 T cell subsets. Nature Immunol. 2003, 4 (3): 225-234. 10.1038/ni889.View ArticleGoogle Scholar
- Mescher MF, Curtsinger JM, Agarwal P, Casey KA, Gerner M, Hammerbeck CD, Popescu F, Xiao Z: Signals required for programming effector and memory development by CD8+ T cells. Immunol Rev. 2006, 211: 81-92. 10.1111/j.0105-2896.2006.00382.x.View ArticlePubMedGoogle Scholar
- Monsurro' V, Wang E, Yamano Y, Migueles SA, Panelli MC, Smith K, Nagorsen D, Connors M, Jacobson S, Marincola FM: Quiescent phenotype of tumor-specific CD8+ T cells following immunization. Blood. 2004, 104: 1970-1978. 10.1182/blood-2004-02-0525.View ArticleGoogle Scholar
- Kawakami Y, Zakut R, Topalian SL, Stotter H, Rosenberg SA: Shared human melanoma antigens. Recognition by tumor- infiltrating lymphocytes in HLA-A2.1-transfected melanomas. J Immunol. 1992, 148: 638-643.PubMedGoogle Scholar
- Lee KH, Wang E, Nielsen MB, Wunderlich J, Migueles.S., Connors M, Steinberg SM, Rosenberg SA, Marincola FM: Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol. 1999, 163: 6292-6300.PubMedGoogle Scholar
- Blattman JN, Grayson JM, Wherry EJ, Kaech SM, Smith SM, Ahmed R: Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat Med. 2003, 9: 540-547. 10.1038/nm866.View ArticlePubMedGoogle Scholar
- Panelli MC, Wang E, Phan G, Puhlman M, Miller L, Ohnmacht GA, Klein H, Marincola FM: Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol. 2002, 3: RESEARCH0035-10.1186/gb-2002-3-7-research0035.PubMed CentralView ArticlePubMedGoogle Scholar
- Panelli MC, Stashower M, Slade HB, Smith K, Norwood C, Abati A, Fetsch PA, Filie A, Walters SA, Astry C, Arico E, Zhao Y, Selleri S, Wang E, Marincola FM: Sequential gene profiling of basal cell carcinomas treated with Imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol. 2006, 8: R8-10.1186/gb-2007-8-1-r8.View ArticleGoogle Scholar
- Sarwal M, Chua MS, Kambham N, Hsieh SC, Satterwhite T, Masek M, Salvatierra O: Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med. 2003, 349: 125-138. 10.1056/NEJMoa035588.View ArticlePubMedGoogle Scholar
- Smith MW, Yue ZN, Korth MJ, Do HA, Boix L, Fausto N, Bruix J, Carithers RL, Katze MG: Hepatitis C virus and liver disease: global transcriptional profiling and identification of potential markers. Hepatology. 2003, 38: 1458-1467.View ArticlePubMedGoogle Scholar
- Mantovani A, Romero P, Palucka AK, Marincola FM: Tumor immunity: effector response to tumor and the influence of the microenvironment. Lancet. 2008, 371: 771-783. 10.1016/S0140-6736(08)60241-X.View ArticlePubMedGoogle Scholar
- Jin P, Wang E, Provenzano M, Deola S, Selleri S, Jiaqiang R, Voiculescu S, Stroncek DF, Panelli MC, Marincola FM: Molecular signatures induced by interleukin-2 on peripheral blood mononuclear cells and T cell subsets. J Transl Med. 2006, 4: 26-10.1186/1479-5876-4-26.PubMed CentralView ArticlePubMedGoogle Scholar
- Adams S, Robbins FM, Chen D, Wagage D, Holbeck SL, Morse HC, Stroncek D, Marincola FM: HLA class I and II genotype of the NCI-60 cell lines. J Transl Med. 2005, 3: 11-10.1186/1479-5876-3-11.PubMed CentralView ArticlePubMedGoogle Scholar
- Wang E, Miller L, Ohnmacht GA, Liu E, Marincola FM: High fidelity mRNA amplification for gene profiling using cDNA microarrays. Nature Biotech. 2000, 18 (4): 457-459. 10.1038/74546.View ArticleGoogle Scholar
- Wang E: RNA amplification for successful gene profiling analysis. J Transl Med. 2005, 3: 28-10.1186/1479-5876-3-28.PubMed CentralView ArticlePubMedGoogle Scholar
- Jin P, Zhao Y, Ngalame Y, Panelli MC, Nagorsen D, Monsurro' V, Smith K, Hu N, Su H, Taylor PR, Marincola FM, Wang E: Selection and validation of endogenous reference genes using a high throughput approach. BMC Genomics. 2004, 5: 55-10.1186/1471-2164-5-55.PubMed CentralView ArticlePubMedGoogle Scholar
- NCI NIH: BRB ArrayTool Site. http://www linus nci nih gov/BRB-ArrayTools html. 2006Google Scholar
- Haring JS, Corbin GA, Harty JT: Dynamic regulation of IFN-gamma signaling in antigen-specific CD8+ T cells responding to infection. J Immunol. 2005, 174: 6791-6802.View ArticlePubMedGoogle Scholar
- Bernabei P, Allione A, Rigamonti L, Bosticardo M, Losana G, Borghi I, Forni G, Novelli F: Regulation of interferon-gamma receptor (INF-gammaR) chains: a peculiar way to rule the life and death of human lymphocytes. Eur Cytokine Netw. 2001, 12: 6-14.PubMedGoogle Scholar
- Shi Y, Liu CH, Roberts AI, Das J, Xu G, Ren G, Zhang Y, Zhang L, Yuan ZR, Tan HS, Das G, Devadas S: Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know. Cell Res. 2006, 16: 126-133. 10.1038/sj.cr.7310017.View ArticlePubMedGoogle Scholar
- Eager R, Nemunaitis J: GM-CSF gene-transduced tumor vaccines. Mol Ther. 2005, 12: 18-27. 10.1016/j.ymthe.2005.02.012.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.